Clavamox is approved for treatment of the following canine infections:
Skin and soft-tissue infections such as wounds, abscesses, cellulitis, and superficial/juvenile and deep

pyoderma due to susceptible strains of the following organisms: lactamase-producing Staphylococcus aureus,

non-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp. and E. coli.
Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.